Cimerli Disease Interactions
There are 2 disease interactions with Cimerli (ranibizumab ophthalmic).
Intravitreal injections (applies to Cimerli) ocular infections
Major Potential Hazard, High plausibility. Applicable conditions: Uveitis, Orbital Infection, Infectious Endophthalmitis, Infectious Optic Neuritis
Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.
Ranibizumab intravitreal injection (applies to Cimerli) increased intraocular pressure
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension
Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.
Switch to professional interaction data
Cimerli drug interactions
There is 1 drug interaction with Cimerli (ranibizumab ophthalmic).
More about Cimerli (ranibizumab ophthalmic)
- Cimerli consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-angiogenic ophthalmic agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Syfovre
Syfovre (pegcetacoplan) treatment for geographic atrophy (GA) a form of dry age-related macular ...
Eylea
Eylea is used to treat neovascular (wet) age-related macular degeneration (AMD), macular edema ...
Izervay
Izervay (avacincaptad pegol) is used for treating geographic atrophy (GA) due to age-related ...
Vabysmo
Vabysmo eye injection is used to treat eye diseases neovascular (wet) age-related macular ...
Ozurdex
Ozurdex is an implant injected into the eye to treat swelling that may occur when there is a ...
Aflibercept ophthalmic
Aflibercept is an injectable eye preparation that may be given by a healthcare provider every one ...
Fluocinolone ophthalmic
Fluocinolone ophthalmic is used for diabetic macular edema, uveitis, posterior
Triamcinolone ophthalmic
Triamcinolone ophthalmic is used for macular edema, temporal arteritis, uveitis, vitrectomy
Dexamethasone ophthalmic
Dexamethasone ophthalmic is used for conjunctivitis, conjunctivitis, allergic, cyclitis, diabetic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.